Satsuma Pharmaceuticals Inc

Satsuma Pharmaceuticals — Technical Presentation (November 2022)

23 slides from Satsuma Pharmaceuticals's technical presentation, Nov 14, 2022

  1. Slide 1: STS101 SUMMIT Phase 3 efficacy trial topline results

    STS101 for the acute treatment of migraine SUMMIT Phase 3 efficacy trial topline results November 14, 2022 conference call Exhibit 99.2

  2. Slide 2: Disclaimer

    Disclaimer Important Notice This Presentation contains forward-looking statements concerning the business, operations and financial performance and condition of Satsuma Pharmaceuticals, Inc. (the “Company”), as well as the Company’s plans, objectives and expectations for its business operations and

  3. Slide 3: Summary: STS101 (DHE nasal powder) and next steps

    Large and growing multi-billion dollar market Summary STS101 (DHE nasal powder) Next steps 10/31/22 cash: $59.4M Developing innovative and differentiated treatment Satsuma does not plan to invest in commercializing STS101 We believe STS101 is approvable based on Ph1 and ASCEND results 40M U.S. preva

  4. Slide 4: STS101 SUMMIT Phase 3 trial results

    STS101 SUMMIT Phase 3 trial results

  5. Slide 5: SUMMIT trial design

    SUMMIT trial design R STS101 5.2 mg* Placebo* up to 30 days 56 days Within 10 days of treatment Screening Randomization & treatment End-of-study visit * All investigative product utilized improved, second-generation nasal delivery device (“Mk2”) End-of-study visit 1,591 subjects randomized Treat sin

  6. Slide 6: Endpoint definitions

    Endpoint definitions Patients report pain severity in electronic diary on a 4-point scale 0 No Pain 1 Mild Pain 2 Moderate Pain 3 Severe Pain SUMMIT subjects treated migraine attacks with Moderate or Severe Pain (i.e., rated as a “2” or “3”) immediately prior to treatment Pain free: Subject reports

  7. Slide 7: Demographics & migraine history

    Demographics & migraine history Subjects’ demographics and migraine history were representative of typical migraine patient population STS101 Placebo Age (mean; SD) 38.2 yrs (11.4) 38.9 yrs (11.5) Gender (% M/F) 21/79 20/80 Race (%) White African American Asian Other 82.5 12 3.5 2.0 81.4 13.7 3.4 1.

  8. Slide 8: Patient disposition

    Patient disposition STS101 Placebo Randomized 796 795 Modified Intent-to-Treat* 716 708 Safety** 731 729 *Subject treated qualifying migraine attack with study medication and has at least 1 post-treatment diary entry **Subject used study medication

  9. Slide 9: Characteristics of treated migraine attacks

    Characteristics of treated migraine attacks Note: Allodynia was considered present if subject had 2 positive responses in 6 question allodynia questionnaire immediately before study drug administration (Ashkenazi 2007; Tepper 2011) Symptoms just before treatment (% of subjects with symptom) STS101 P

  10. Slide 10: Co-primary endpoints

    Co-primary endpoints MBS: Most-bothersome symptom from among photophobia, phonophobia or nausea declared by subject at time of treated attack Subjects who took study medication, entered efficacy data at any timepoint, but did not report data at 2 hr were imputed to be treatment failures STS101 (n=71

  11. Slide 11: Pain freedom over time (single dose)

    Pain freedom over time (single dose) p=0.1661 p=0.0009 p<0.0001 p<0.0001 p<0.0001 p<0.0001 p=0.0004 STS101 was numerically superior to placebo at all but one time point (1h) Did not achieve statistical significance (p<0.05) at 2h Statistically significant at all time points after 2h Subjects who did

  12. Slide 12: MBS freedom over time (single dose; no rescue medications)

    MBS freedom over time (single dose; no rescue medications) p=0.0552 p=0.0002 p<0.0001 p<0.0001 p<0.0001 p<0.0001 p=0.0001 STS101 was numerically superior to placebo at all but one time point (0.5h) Did not achieve statistical significance (p<0.05) at 2h Statistically significant at all time points a

  13. Slide 13: Pain relief over time (single dose; no rescue medications)

    Pain relief over time (single dose; no rescue medications) p=0.0017 p<0.001 p<0.0001 p=0.0001 p<0.0001 p<0.0001 p=0.0003 STS101 was statistically significant vs placebo (p<0.05) at 2h and all time points thereafter Subjects who did not report data at a timepoint or who used any rescue medication pri

  14. Slide 14: STS101 showed effects on key secondary endpoints

    STS101 showed effects on key secondary endpoints Endpoint p-value Relief from Headache Pain at 2h post-dose (and all timepoints thereafter) 0.0017 (at 2h) Use of rescue medication within 24h and 48h post-dose 0.0001 Sustained freedom from Headache Pain from 2-24h post-dose (with no relapse or use of

  15. Slide 15: Additional and potentially differentiating secondary endpoints

    STS101 showed effects on additional and potentially differentiating secondary endpoints Endpoint p-value Free from pain at 4h (and all timepoints thereafter) in attacks with allodynia at time of treatment 0.022 (at 4h) Free from MBS at 4h (and all timepoints thereafter) in attacks with allodynia at

  16. Slide 16: STS101 exhibited favorable safety and tolerability profile

    STS101 exhibited favorable safety and tolerability profile STS101 Placebo Safety Population (n) 731 729 Treatment-Emergent Adverse Events reported by >1% of subjects Nasal discomfort 8.3% 1.5% Dysgeusia 3.7% 0.3% Nasal congestion 3.1% 0.8% Nausea 1.9% 0.7% Throat irritation 1.1% 0.3% Rhinorrhea 1.1%

  17. Slide 17: Absolute efficacy rates comparable to gepants

    STS101 showed absolute efficacy rates comparable to gepants STS101 / SUMMIT Gepant / Ph3 trials* Pain Free at 2h - Active 20.4% 19.2% – 21.8% Pain Free at 2h - Placebo 17.5% 11.8% - 14.3% MBS Free at 2h - Active 37.8% 35.1% - 38.8% MBS Free at 2h - Placebo 32.9% 25.2% - 27.7% However, placebo respon

  18. Slide 18: Summary and conclusions

    Summary and conclusions SUMMIT was a rigorously-conducted, large, placebo-controlled trial that addressed factors thought to contribute to previous EMERGE trial failing to achieve statistical significance on co-primary endpoints at 2h STS101 did not demonstrate statistical significance over placebo

  19. Slide 19: Summary and conclusions

    Summary and conclusions SUMMIT results suggest STS101 may have particular utility for people with migraine who experience: Attacks with allodynia Long-duration migraine attacks, including menstrually-associated migraine Nausea STS101 may be an attractive treatment option for patients who: Desire a l

  20. Slide 20: STS101 program and plans

    @atsuma pharmaceuticals STS101 program and plans

  21. Slide 21: STS101 program and plans

    STS101 program and plans STS101 is a differentiated asset Satsuma has established automated, commercial-scale manufacturing capability for STS101 Based on feedback from three meetings with FDA, Satsuma believes Phase 1 PK and ASCEND long-term, open-label safety trials will support NDA filing and pot

  22. Slide 22: Next steps

    Next steps Complete analysis of SUMMIT trial results Potential NDA filing (Q1 2023) Actively explore alternatives to maximize value for shareholders Minimize cash expenditures

  23. Slide 23: Thank you

    @atsuma pharmaceuticals Thank you

Satsuma Pharmaceuticals — Technical Presentation (November 2022) on 6ix